{"type":"trials","record":{"id":11,"source_id":"clinicaltrials-gov","external_id":"NCT06789900","title":"Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women","brief_summary":"It is estimated that women lose around 20-25% of bone mass during the 5-10 years period of postmenopausal transition, and menopause is considered a major risk factor for osteoporotic fragility fracture. Currently, there is no preventive strategy to counteract these changes, and hormone replacement therapy is not considered an attractive option for many women, because of concerns related to side effects. Rapamycin, through inhibition of mTOR (the mechanistic target of Rapamycin) has been demonstrated in many preclinical animal models to extend lifespan and healthspan. The most well-established mTOR inhibitors include rapamycin (sirolimus) and its analog (also referred as rapalog). Everolimus are FDA approved and have been used for many years at a high dose as an immunosuppressant and anti-cancer drug. Exercise training has been demonstrated to counteract age-related degenerative changes…","overall_status":"Active Not Recruiting","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Odense University Hospital","enrollment":136,"countries":["Denmark"],"start_date":"2024-10-14","completion_date":"2026-10-01","last_update_date":"2026-04-07","source_url":"https://clinicaltrials.gov/study/NCT06789900","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-14T02:44:58.543517+00:00","last_seen_at":"2026-09-15T00:18:31.508+00:00","metadata":{"acronym":"RapaLoad","organization":"Odense University Hospital","source_has_results":false},"controlled_terms":[],"relevance_confidence":80,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Published automatically with 80% topic confidence after controlled-term evaluation.","quality_checked_at":"2026-09-15T02:15:56.576005+00:00","duplicate_cluster_key":"registry:nct06789900","duplicate_of_id":null,"clinical_trial_topics":[{"topic_slug":"rapamycin","is_published":true,"match_reasons":["Legacy trial evaluated automatically against controlled title, summary, and longevity-context rules."],"matched_fields":["title"],"relevance_score":80,"intelligence_topics":{"name":"Rapamycin","slug":"rapamycin"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/11","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}